Biogen Idec ($BIIB) has struck a far-reaching agreement with CRO giant Quintiles ($Q), tapping the contractor to help design, plan and run its Phase II-IV studies. Under the 5-year agreement, Quintiles is on hand to boost the transparency, quality and success of Biogen's R&D endeavors, the companies said, mirroring a similarly deep-seated arrangement with Merck KGaA last year. More